Zevra Therapeutics (ZVRA) Competitors $9.13 -0.24 (-2.56%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.23 +0.10 (+1.10%) As of 06/13/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. AGIO, INDV, IDYA, BLTE, TWST, APGE, IMCR, BEAM, TARS, and GLPGShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Agios Pharmaceuticals (AGIO), Indivior (INDV), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Twist Bioscience (TWST), Apogee Therapeutics (APGE), Immunocore (IMCR), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Agios Pharmaceuticals Indivior IDEAYA Biosciences Belite Bio Twist Bioscience Apogee Therapeutics Immunocore Beam Therapeutics Tarsus Pharmaceuticals Galapagos Zevra Therapeutics (NASDAQ:ZVRA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings. Which has more risk and volatility, ZVRA or AGIO? Zevra Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Does the media prefer ZVRA or AGIO? In the previous week, Agios Pharmaceuticals had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 7 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.29 beat Agios Pharmaceuticals' score of 0.41 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has better earnings & valuation, ZVRA or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$40.59M12.30-$46.05M-$1.90-4.81Agios Pharmaceuticals$37.04M53.64$673.72M$11.243.05 Is ZVRA or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,845.92% compared to Zevra Therapeutics' net margin of -342.63%. Agios Pharmaceuticals' return on equity of -2.51% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-342.63% -159.54% -51.50% Agios Pharmaceuticals 1,845.92%-2.51%-2.26% Do institutionals & insiders have more ownership in ZVRA or AGIO? 35.0% of Zevra Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ZVRA or AGIO? Zevra Therapeutics currently has a consensus target price of $22.29, suggesting a potential upside of 144.09%. Agios Pharmaceuticals has a consensus target price of $58.60, suggesting a potential upside of 70.85%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the MarketBeat Community believe in ZVRA or AGIO? Agios Pharmaceuticals received 453 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Zevra Therapeutics an outperform vote while only 66.67% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes3995.12% Underperform Votes24.88%Agios PharmaceuticalsOutperform Votes49266.67% Underperform Votes24633.33% SummaryAgios Pharmaceuticals beats Zevra Therapeutics on 10 of the 19 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$499.23M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-4.638.4326.6319.64Price / Sales12.30262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book5.346.536.964.60Net Income-$46.05M$143.25M$3.23B$248.06M7 Day Performance-1.40%-0.06%-1.13%-0.94%1 Month Performance12.16%11.77%8.59%3.52%1 Year Performance96.34%3.66%33.63%14.02% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.8553 of 5 stars$9.13-2.6%$22.29+144.1%+85.9%$499.23M$40.59M-4.6320Positive NewsAnalyst RevisionAGIOAgios Pharmaceuticals3.9419 of 5 stars$34.33+2.2%$56.50+64.6%-26.7%$1.99B$37.04M3.03390Analyst RevisionINDVIndivior2.451 of 5 stars$14.07+3.5%$15.00+6.6%-14.7%$1.94B$1.17B-40.201,164Positive NewsIDYAIDEAYA Biosciences3.9444 of 5 stars$21.73+3.0%$54.27+149.8%-43.0%$1.90B$7M-6.5880Analyst RevisionGap DownBLTEBelite Bio2.8044 of 5 stars$59.68-7.1%$96.67+62.0%+18.9%$1.90BN/A-53.7710Positive NewsShort Interest ↑Analyst RevisionTWSTTwist Bioscience4.1064 of 5 stars$31.57+4.1%$50.40+59.6%-35.6%$1.89B$347.68M-9.34990Gap DownAPGEApogee Therapeutics2.4035 of 5 stars$40.98+8.8%$94.60+130.8%+3.2%$1.89BN/A-16.9391Positive NewsGap DownHigh Trading VolumeIMCRImmunocore3.0509 of 5 stars$37.25-2.0%$58.89+58.1%-12.6%$1.87B$333.58M-39.21320Positive NewsAnalyst UpgradeAnalyst RevisionBEAMBeam Therapeutics3.2325 of 5 stars$18.58+9.3%$48.75+162.4%-32.4%$1.87B$63.58M-10.56510Analyst RevisionGap DownHigh Trading VolumeTARSTarsus Pharmaceuticals2.1287 of 5 stars$43.92-0.4%$66.67+51.8%+23.4%$1.85B$233.67M-11.5350GLPGGalapagos0.2658 of 5 stars$27.73-0.8%$25.33-8.6%+11.8%$1.84B$288.19M0.001,310 Related Companies and Tools Related Companies Agios Pharmaceuticals Alternatives Indivior Alternatives IDEAYA Biosciences Alternatives Belite Bio Alternatives Twist Bioscience Alternatives Apogee Therapeutics Alternatives Immunocore Alternatives Beam Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Galapagos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
